

Domenico Penna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3881049/publications.pdf>

Version: 2024-02-01

20
papers

359
citations

1039406

9
h-index

940134

16
g-index

20
all docs

20
docs citations

20
times ranked

582
citing authors

#	ARTICLE	IF	CITATIONS
1	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	2.5	28
2	SFLT4 levels in COVID-19 patients: Association with outcome and thrombosis. <i>American Journal of Hematology</i> , 2021, 96, E41-E43.	2.0	11
3	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. <i>Blood Cancer Journal</i> , 2019, 9, 12.	2.8	52
4	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. <i>Leukemia</i> , 2019, 33, 2522-2553.	3.3	1
5	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Mayo Clinic Proceedings</i> , 2019, 94, 599-610.	1.4	103
6	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. <i>American Journal of Hematology</i> , 2019, 94, 286-290.	2.0	10
7	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E164-E167.	2.0	1
8	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46
9	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. <i>Blood Cancer Journal</i> , 2018, 8, 118.	2.8	7
10	Genetic predictors of response to specific drugs in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2018, 8, 120.	2.8	1
11	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. <i>American Journal of Hematology</i> , 2018, 93, 1474-1484.	2.0	56
12	Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. <i>Blood Advances</i> , 2018, 2, 1980-1984.	2.5	13
13	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
14	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , 2018, 132, 3035-3035.	0.6	1
15	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. <i>Blood</i> , 2018, 132, 3040-3040.	0.6	1
16	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. <i>Blood</i> , 2018, 132, 4300-4300.	0.6	0
17	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. <i>Blood</i> , 2018, 132, 3034-3034.	0.6	0
18	The Germline JAK2 G662E Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. <i>Blood</i> , 2018, 132, 1761-1761.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. <i>Blood</i> , 2018, 132, 3033-3033.	0.6	0
20	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , 2018, 132, 3044-3044.	0.6	0